304 related articles for article (PubMed ID: 21209915)
1. Inactivation of the FLCN tumor suppressor gene induces TFE3 transcriptional activity by increasing its nuclear localization.
Hong SB; Oh H; Valera VA; Baba M; Schmidt LS; Linehan WM
PLoS One; 2010 Dec; 5(12):e15793. PubMed ID: 21209915
[TBL] [Abstract][Full Text] [Related]
2. TFE3 Xp11.2 Translocation Renal Cell Carcinoma Mouse Model Reveals Novel Therapeutic Targets and Identifies GPNMB as a Diagnostic Marker for Human Disease.
Baba M; Furuya M; Motoshima T; Lang M; Funasaki S; Ma W; Sun HW; Hasumi H; Huang Y; Kato I; Kadomatsu T; Satou Y; Morris N; Karim BO; Ileva L; Kalen JD; Wilan Krisna LA; Hasumi Y; Sugiyama A; Kurahashi R; Nishimoto K; Oyama M; Nagashima Y; Kuroda N; Araki K; Eto M; Yao M; Kamba T; Suda T; Oike Y; Schmidt LS; Linehan WM
Mol Cancer Res; 2019 Aug; 17(8):1613-1626. PubMed ID: 31043488
[TBL] [Abstract][Full Text] [Related]
3. PRDM10 RCC: A Birt-Hogg-Dubé-like Syndrome Associated With Lipoma and Highly Penetrant, Aggressive Renal Tumors Morphologically Resembling Type 2 Papillary Renal Cell Carcinoma.
Schmidt LS; Vocke CD; Ricketts CJ; Blake Z; Choo KK; Nielsen D; Gautam R; Crooks DR; Reynolds KL; Krolus JL; Bashyal M; Karim B; Cowen EW; Malayeri AA; Merino MJ; Srinivasan R; Ball MW; Zbar B; Marston Linehan W
Urology; 2023 Sep; 179():58-70. PubMed ID: 37331486
[TBL] [Abstract][Full Text] [Related]
4. FLCN alteration drives metabolic reprogramming towards nucleotide synthesis and cyst formation in salivary gland.
Isono Y; Furuya M; Kuwahara T; Sano D; Suzuki K; Jikuya R; Mitome T; Otake S; Kawahara T; Ito Y; Muraoka K; Nakaigawa N; Kimura Y; Baba M; Nagahama K; Takahata H; Saito I; Schmidt LS; Linehan WM; Kodama T; Yao M; Oridate N; Hasumi H
Biochem Biophys Res Commun; 2020 Feb; 522(4):931-938. PubMed ID: 31806376
[TBL] [Abstract][Full Text] [Related]
5. Distinctive expression patterns of glycoprotein non-metastatic B and folliculin in renal tumors in patients with Birt-Hogg-Dubé syndrome.
Furuya M; Hong SB; Tanaka R; Kuroda N; Nagashima Y; Nagahama K; Suyama T; Yao M; Nakatani Y
Cancer Sci; 2015 Mar; 106(3):315-23. PubMed ID: 25594584
[TBL] [Abstract][Full Text] [Related]
6. Folliculin impairs breast tumor growth by repressing TFE3-dependent induction of the Warburg effect and angiogenesis.
El-Houjeiri L; Biondini M; Paquette M; Kuasne H; Pacis A; Park M; Siegel PM; Pause A
J Clin Invest; 2021 Nov; 131(22):. PubMed ID: 34779410
[TBL] [Abstract][Full Text] [Related]
7. The tumor suppressor FLCN mediates an alternate mTOR pathway to regulate browning of adipose tissue.
Wada S; Neinast M; Jang C; Ibrahim YH; Lee G; Babu A; Li J; Hoshino A; Rowe GC; Rhee J; Martina JA; Puertollano R; Blenis J; Morley M; Baur JA; Seale P; Arany Z
Genes Dev; 2016 Nov; 30(22):2551-2564. PubMed ID: 27913603
[TBL] [Abstract][Full Text] [Related]
8. Loss of FLCN inhibits canonical WNT signaling via TFE3.
Kennedy JC; Khabibullin D; Hougard T; Nijmeh J; Shi W; Henske EP
Hum Mol Genet; 2019 Oct; 28(19):3270-3281. PubMed ID: 31272105
[TBL] [Abstract][Full Text] [Related]
9. Cathepsin-K immunoreactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas.
Martignoni G; Pea M; Gobbo S; Brunelli M; Bonetti F; Segala D; Pan CC; Netto G; Doglioni C; Hes O; Argani P; Chilosi M
Mod Pathol; 2009 Aug; 22(8):1016-22. PubMed ID: 19396149
[TBL] [Abstract][Full Text] [Related]
10. GPNMB expression identifies TSC1/2/mTOR-associated and MiT family translocation-driven renal neoplasms.
Salles DC; Asrani K; Woo J; Vidotto T; Liu HB; Vidal I; Matoso A; Netto GJ; Argani P; Lotan TL
J Pathol; 2022 Jun; 257(2):158-171. PubMed ID: 35072947
[TBL] [Abstract][Full Text] [Related]
11. TFEB and TFE3 drive kidney cystogenesis and tumorigenesis.
Di Malta C; Zampelli A; Granieri L; Vilardo C; De Cegli R; Cinque L; Nusco E; Pece S; Tosoni D; Sanguedolce F; Sorrentino NC; Merino MJ; Nielsen D; Srinivasan R; Ball MW; Ricketts CJ; Vocke CD; Lang M; Karim B; Lanfrancone L; Schmidt LS; Linehan WM; Ballabio A
EMBO Mol Med; 2023 May; 15(5):e16877. PubMed ID: 36987696
[TBL] [Abstract][Full Text] [Related]
12. Loss of FLCN-FNIP1/2 induces a non-canonical interferon response in human renal tubular epithelial cells.
Glykofridis IE; Knol JC; Balk JA; Westland D; Pham TV; Piersma SR; Lougheed SM; Derakhshan S; Veen P; Rooimans MA; van Mil SE; Böttger F; Poddighe PJ; van de Beek I; Drost J; Zwartkruis FJ; de Menezes RX; Meijers-Heijboer HE; Houweling AC; Jimenez CR; Wolthuis RM
Elife; 2021 Jan; 10():. PubMed ID: 33459596
[TBL] [Abstract][Full Text] [Related]
13. Tumor suppressor FLCN inhibits tumorigenesis of a FLCN-null renal cancer cell line and regulates expression of key molecules in TGF-beta signaling.
Hong SB; Oh H; Valera VA; Stull J; Ngo DT; Baba M; Merino MJ; Linehan WM; Schmidt LS
Mol Cancer; 2010 Jun; 9():160. PubMed ID: 20573232
[TBL] [Abstract][Full Text] [Related]
14. Renal tumour suppressor function of the Birt-Hogg-Dubé syndrome gene product folliculin.
Hudon V; Sabourin S; Dydensborg AB; Kottis V; Ghazi A; Paquet M; Crosby K; Pomerleau V; Uetani N; Pause A
J Med Genet; 2010 Mar; 47(3):182-9. PubMed ID: 19843504
[TBL] [Abstract][Full Text] [Related]
15. Regulation of mitochondrial oxidative metabolism by tumor suppressor FLCN.
Hasumi H; Baba M; Hasumi Y; Huang Y; Oh H; Hughes RM; Klein ME; Takikita S; Nagashima K; Schmidt LS; Linehan WM
J Natl Cancer Inst; 2012 Nov; 104(22):1750-64. PubMed ID: 23150719
[TBL] [Abstract][Full Text] [Related]
16. TFE3 fusions escape from controlling of mTOR signaling pathway and accumulate in the nucleus promoting genes expression in Xp11.2 translocation renal cell carcinomas.
Yin X; Wang B; Gan W; Zhuang W; Xiang Z; Han X; Li D
J Exp Clin Cancer Res; 2019 Mar; 38(1):119. PubMed ID: 30849994
[TBL] [Abstract][Full Text] [Related]
17. Birt-Hogg-Dubé: tumour suppressor function and signalling dynamics central to folliculin.
Tee AR; Pause A
Fam Cancer; 2013 Sep; 12(3):367-72. PubMed ID: 23096221
[TBL] [Abstract][Full Text] [Related]
18. Folliculin-interacting proteins Fnip1 and Fnip2 play critical roles in kidney tumor suppression in cooperation with Flcn.
Hasumi H; Baba M; Hasumi Y; Lang M; Huang Y; Oh HF; Matsuo M; Merino MJ; Yao M; Ito Y; Furuya M; Iribe Y; Kodama T; Southon E; Tessarollo L; Nagashima K; Haines DC; Linehan WM; Schmidt LS
Proc Natl Acad Sci U S A; 2015 Mar; 112(13):E1624-31. PubMed ID: 25775561
[TBL] [Abstract][Full Text] [Related]
19. High-throughput and targeted drug screens identify pharmacological candidates against MiT-translocation renal cell carcinoma.
Lang M; Schmidt LS; Wilson KM; Ricketts CJ; Sourbier C; Vocke CD; Wei D; Crooks DR; Yang Y; Gibbs BK; Zhang X; Klumpp-Thomas C; Chen L; Guha R; Ferrer M; McKnight C; Itkin Z; Wangsa D; Wangsa D; James A; Difilippantonio S; Karim B; Morís F; Ried T; Merino MJ; Srinivasan R; Thomas CJ; Linehan WM
J Exp Clin Cancer Res; 2023 Apr; 42(1):99. PubMed ID: 37095531
[TBL] [Abstract][Full Text] [Related]
20. Birt-Hogg-Dubé syndrome: Clinical and molecular aspects of recently identified kidney cancer syndrome.
Hasumi H; Baba M; Hasumi Y; Furuya M; Yao M
Int J Urol; 2016 Mar; 23(3):204-10. PubMed ID: 26608100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
